GR3006319T3 - - Google Patents

Info

Publication number
GR3006319T3
GR3006319T3 GR920402682T GR920402682T GR3006319T3 GR 3006319 T3 GR3006319 T3 GR 3006319T3 GR 920402682 T GR920402682 T GR 920402682T GR 920402682 T GR920402682 T GR 920402682T GR 3006319 T3 GR3006319 T3 GR 3006319T3
Authority
GR
Greece
Prior art keywords
show
ocular
pgs
prostaglandins
keto
Prior art date
Application number
GR920402682T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26532381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3006319(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3006319T3 publication Critical patent/GR3006319T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR920402682T 1987-09-18 1992-11-24 GR3006319T3 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23589087 1987-09-18
JP33403787 1987-12-29

Publications (1)

Publication Number Publication Date
GR3006319T3 true GR3006319T3 (enExample) 1993-06-21

Family

ID=26532381

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402682T GR3006319T3 (enExample) 1987-09-18 1992-11-24

Country Status (11)

Country Link
US (1) US5001153A (enExample)
EP (2) EP0308135B1 (enExample)
JP (2) JPH02108A (enExample)
KR (1) KR930000051B1 (enExample)
AT (2) ATE108330T1 (enExample)
CA (1) CA1328075C (enExample)
DE (2) DE3850676T2 (enExample)
ES (1) ES2052735T3 (enExample)
GB (1) GB2209939B (enExample)
GR (1) GR3006319T3 (enExample)
NZ (1) NZ226197A (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
EP1300150A3 (en) * 1988-09-06 2003-05-14 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
ATE111736T1 (de) * 1988-10-01 1994-10-15 R Tech Ueno Ltd Okulare hypotensive mittel.
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE122563T1 (de) * 1989-07-27 1995-06-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-keto-prostansäure-derivaten zur herstellung eines medikaments für die verbesserung der ausscheidung des kaliumions.
CA2022372C (en) * 1989-08-09 2000-05-02 Ryuji Ueno Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
KR100224951B1 (ko) * 1990-03-08 1999-10-15 시오노 요시히코 15-데옥시프로스타글란딘유도체
TW224942B (enExample) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
US5166175A (en) * 1990-05-22 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination
ATE114470T1 (de) * 1990-05-22 1994-12-15 R Tech Ueno Ltd Behandlung von intraocularem druck mit einer synergistischen kombination zur ophthalmischen verwendung.
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
ATE91419T1 (de) * 1990-05-22 1993-07-15 R Tech Ueno Ltd Synergistische kombination zur ophthalmischen verwendung.
ES2069823T3 (es) * 1990-05-22 1995-05-16 R Tech Ueno Ltd Tratamiento de la hipertension ocular con una combinacion sinergica ocular.
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
TW210287B (enExample) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
DK0503887T3 (da) * 1991-03-14 1996-09-16 R Tech Ueno Ltd Fremme af sårheling med 15-ketoprostaglandinforbindelser
CA2065889C (en) * 1991-10-02 2002-08-27 Tetsuya Sugiyama Increasing the choroidal blood flow
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
FR2707295A1 (fr) * 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5387608A (en) * 1993-08-17 1995-02-07 Allergan, Inc. Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
CA2138181A1 (en) * 1993-12-15 1995-06-16 Verney L. Sallee Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
DE69705421T2 (de) 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
CN1237157A (zh) 1996-11-12 1999-12-01 阿尔康实验室公司 作为眼压降低剂的前列腺素的顺式－△4类似物
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
JP2001514628A (ja) 1997-03-07 2001-09-11 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療に用いるための１３−チアプロスタグランジン
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
ES2265166T3 (es) 1997-10-13 2007-02-01 R-Tech Ueno, Ltd. Composicion para tratamiento de hipertension intraocular o glaucoma.
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
JP5011548B2 (ja) * 1998-12-25 2012-08-29 株式会社アールテック・ウエノ 高眼圧症あるいは緑内障の処置用医薬組成物
SE9900672D0 (sv) 1999-02-25 1999-02-25 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
WO2001046134A1 (en) * 1999-12-22 2001-06-28 Alcon Universal Ltd. 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
EP1251862B1 (en) 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
HUP0300391A3 (en) * 2000-03-16 2008-05-28 Sucampo Ag Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
JP2003527430A (ja) * 2000-03-24 2003-09-16 スカンポ・アクチェンゲゼルシャフト １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery
EP1321144B1 (en) * 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
AU2003216547A1 (en) * 2002-03-15 2003-09-29 Merck And Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2003105847A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20050239787A1 (en) * 2002-06-17 2005-10-27 Goetz Michael A Novel maxi-k channel blockers, methods of use and process for making the same
EP1515974A4 (en) * 2002-06-17 2007-02-28 Merck & Co Inc NEW MAXI-K CHANNEL BLOCKS, METHOD OF USE AND METHOD FOR THE PRODUCTION THEREOF
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
WO2004019938A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
TWI337881B (en) * 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
JP2006505572A (ja) * 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
CN1791402A (zh) * 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
US20060199863A1 (en) * 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
DE602004023106D1 (de) 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
ATE555792T1 (de) * 2004-12-24 2012-05-15 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivat enthaltende produkte
CA2589081C (en) * 2004-12-29 2013-03-19 Masato Iino Composition and method for scalp and hair treatment
DK1853271T3 (da) * 2005-03-04 2011-01-24 Sucampo Ag Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
JP4648340B2 (ja) * 2006-02-07 2011-03-09 株式会社アールテック・ウエノ １５−ケトプロスタグランジンｅ誘導体の製造法
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
MY150518A (en) 2008-04-24 2014-01-30 Allergan Inc Substituted gamma lactams as therapeutic agents
US7713968B2 (en) 2008-04-24 2010-05-11 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ628266A (en) * 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
EP2600825B1 (en) 2010-08-02 2018-12-12 Ac Patent Holding Inc. Method for curling hair
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
JP2014510022A (ja) 2011-04-07 2014-04-24 スキャンポ・アーゲー 眼精疲労の処置方法
JP6193230B2 (ja) * 2011-08-05 2017-09-06 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 統合失調症の処置方法
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
WO2016063184A1 (en) 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476661A (en) * 1974-05-13 1977-06-16 American Cyanamid Co Prostaglandins
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
ES2053458T3 (es) * 1986-03-13 1994-08-01 Univ Columbia Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma.
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) * 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
JPS6453101A (en) * 1987-05-25 1989-03-01 Kurashiki Boseki Kk Equal tilt angle interference type film thickness gauge
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化

Also Published As

Publication number Publication date
GB8821104D0 (en) 1988-10-05
EP0455264A3 (en) 1991-11-27
US5001153A (en) 1991-03-19
EP0308135A3 (en) 1989-06-14
GB2209939A (en) 1989-06-01
JP2592204B2 (ja) 1997-03-19
ATE82499T1 (de) 1992-12-15
EP0308135B1 (en) 1992-11-19
NZ226197A (en) 1992-02-25
KR930000051B1 (ko) 1993-01-06
EP0308135A2 (en) 1989-03-22
CA1328075C (en) 1994-03-29
AU600168B2 (en) 1990-08-02
GB2209939B (en) 1992-01-02
DE3850676D1 (de) 1994-08-18
DE3876050D1 (de) 1992-12-24
DE3876050T2 (de) 1993-03-25
JPH0680571A (ja) 1994-03-22
KR890004707A (ko) 1989-05-09
DE3850676T2 (de) 1994-11-03
ES2052735T3 (es) 1994-07-16
AU2231388A (en) 1989-03-23
JPH02108A (ja) 1990-01-05
ATE108330T1 (de) 1994-07-15
JPH0571567B2 (enExample) 1993-10-07
EP0455264A2 (en) 1991-11-06
EP0455264B1 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
EP0308135A3 (en) Ocular hypotensive agents
PH25056A (en) 4,5,6-substituted-n-(substituted-phenyl)-2-pyrimidinamines
TW218869B (enExample)
MA21216A1 (fr) Compositions de blanchiment.
DE3581858D1 (en) 1,4-dihydropyridine.
DE3883627D1 (de) 1,4-Dihydropyridin-Enantiomere.
FI853255L (fi) Foerfarande foer framstaellning av 6-klor-n-metyl-2,3,4,5-tetrahydro-1h-3-bensazepin.
ZA893346B (en) Anticoagulant peptide alcohols
GR3006694T3 (enExample)
FI883266A0 (fi) 4-aminosubstituerade 1,2-dihydronaftalenderivat.
PH30773A (en) Novel substituted thienopyrans antihypertensive agents.
FI883935L (fi) Foerfarande foer framstaellning av 1,6-di (n3-cyano-n1-guanidino) hexan.
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
IT8420775V0 (it) Corpo musicale, nonche' di illuminazione, automatico.
DE69018308D1 (de) Antischaum-Zusammensetzungen.
ZA887306B (en) 1(2h)-phthalazinones as cytoprotective agents
FI902192A0 (fi) Foerfarande foer framstaellning av 1,3-dihydro-4-pyridinyl-2h-imidazol-2-oner.
IE873358L (en) Launddry compositions.
IT8741520A0 (it) 2-osso-4-(2'-difluorometiltiofenil)-5-metassicarbonil-6-metil-1,2,3,4tetraidropirimidina.
CS1003186A1 (en) Zpusob vyroby 1,6 disubstituovanych n ( 8alfa ergolinyl .p n, n, diethylmocovin
ATE93851T1 (de) 1,4-dihydropyridin-enantiomere.
IE871800L (en) Bisphosphonate compositions.